1. Home
  2. GLQ vs RCEL Comparison

GLQ vs RCEL Comparison

Compare GLQ & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

GLQ

Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

HOLD

Current Price

$8.56

Market Cap

159.3M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.18

Market Cap

129.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLQ
RCEL
Founded
2005
N/A
Country
United States
United States
Employees
N/A
226
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.3M
129.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GLQ
RCEL
Price
$8.56
$4.18
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
91.7K
265.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
11.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.66
$3.22
52 Week High
$8.73
$7.12

Technical Indicators

Market Signals
Indicator
GLQ
RCEL
Relative Strength Index (RSI) 57.15 46.29
Support Level $7.99 $4.00
Resistance Level $8.55 $4.57
Average True Range (ATR) 0.12 0.33
MACD -0.00 -0.01
Stochastic Oscillator 59.13 29.03

Price Performance

Historical Comparison
GLQ
RCEL

About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: